Aiwell Nordic Aps
Ole Maaløes Vej 3, 2200 København N, CVR 41699094
Rank Profit for the year
Rank in industry
17/35
"Around avg"
Rank in Denmark
266,677/334,976
"Lowest 35%"
Top management - top 3
| Hiroyuki MABUCHI 1 | CEO |
| Yasushi NAKAGAWA 1 | Director |
Legal owners - top 3
| 100% | aiwell Inc. |
Rights certificate
Selskabet tegnes af direktørerne i forening.
Company information based on CVR
| Name | Aiwell Nordic Aps |
|---|---|
| CVR | 41699094 |
| Address | Ole Maaløes Vej 3, 2200 København N |
| Industry | Manufacture of basic pharmaceutical products [211000] |
| Established | 23-09-2020 (2 yr) |
| Company type | Limited Corporation (APS) |
| Number of employees | - |
| Advertising protection | No |
| Auditor | Grant Thornton,Statsautoriseret Revisionspartnerselskab since 23-09-2020 |
| Financial statement period | 01-01 to 31-12 |
| Company capital | 40,000 DKK |
| Articles of assoc. last | 23-09-2020 |
Member of industries
- Manufacture of basic pharmaceutical productsNACE6 containing 41 comp.
- Manufacture of basic pharmaceutical productsNACE3 containing 41 comp.
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE2 containing 255 comp.
- ManufacturingNACE1 containing 26,897 comp.
Purpose
Selskabets formål er at foreta-ge analytiske test af biologiske prøver. R&D, teknisk træning, forskning på bestilling, import, eksport, fremstilling, konditio-nering og salg af diagnostice-rings-/ testkits, farmaceutiske produkter, kvasi-lægemidler, dyremediciner, antistoffer, en-heder. R&D, drift og vedlige-holdelse af lifescience / biolo-giske datamanagement sy-stemer. Fremstilling, leasing og salg af paramedicinske og medicinsk e apparaturer. R&D inden for avanceret medicinsk teknologi. Samt hermed be-slægtet virksomhed.
Financial Statement
| 2020 | |
|---|---|
| Currency/unit | 000' DKK |
| Revenue | - - |
| Gross Profit | -20 - |
| Profit for the year | -20 - |
| Equity | 20 - |
| Total Assets | 40 - |
Mangement review
Development in activities and financial matters
The gross loss for the year totals tDKK -20. Income or loss from the year totals tDKK -20.
Management considers the net loss for the year unsatisfactory
The gross loss for the year totals tDKK -20. Income or loss from the year totals tDKK -20.
Management considers the net loss for the year unsatisfactory
25-06-2021